prof. dr. H.M. (Helena) Verkooijen

prof. dr. H.M. (Helena) Verkooijen

Full Professor
prof. dr. H.M. (Helena) Verkooijen
  • Clinical Trial Office

Research Programs

Strategic Program Cancer



Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology.

Leader (PI) of several international (H2020) research consortia and academic industrial partnership, head of clinical research office and investigator in a range of (international) scientific studies. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, and panel member.

Within the Division of Imaging and Cancer of the UMC Utrecht, I am responsible for clinical evaluation of innovative cancer treatments, and for evaluating to what extent theoretical benefits of these innovations translate into real benefits for patients. I lead a team of post-doc researchers, PhD students, and (medical) graduate students. I also lead the division’s clinical research office, which is responsible for trial support, data management, IT solutions, quality control and medico-ethical advise (supporting 200 academic researchers).

I lead two international consortia (one H2020 European, one transatlantic) and collaborate closely with (international) academic and industry partners. I am regularly invited as speaker at international conferences, educational sessions and consortium meetings, and as panelist at meetings/debates of professional organizations. I serve as a member in several scientific advisory boards and expert committees.

I am Strategic Advisor for 'NTvG Gezonde Zorg', a campaign of the Dutch Journal of Medicine (Nederlands Tijdschrift voor Geneeskunde). This campaign contributes to ensuring sustainability and affordability of health care in the Netherlands by exposing the harms of medicalisation (overdiagnosis and overtreatment) and explicitly demonstrating the power of (primary) prevention. 

Side Activities


  • PI of transatlantic MOMENTUM study, funded by Elekta.
  • Board Member Dutch Breast Cancer Research Group (Borstkanker Onderzoek Groep, BOOG)
  • Member Scientific Advisory Board Dutch Expert Centre for Screening
  • Board Member J.M. Fentener van Vlissingen Fonds
  • Member Scientific Advisory Board Dutch Prospective Colorectal Cancer Cohort (PLCRC)
  • Member Expert Committee Value-Based Health Care Breast Cancer (NFU)

Research Output (334)

Interrater agreement of contouring of the neurovascular bundles and internal pudendal arteries in neurovascular-sparing magnetic resonance-guided radiotherapy for localized prostate cancer

Teunissen F. R., Wortel R. C., Wessels F. J., Claes A., van de Pol S. M.G., Rasing M. J.A., Meijer R. P., van Melick H. H.E., de Boer J. C.J., Verkooijen H. M., van der Voort van Zyp J. R.N. jan 2022, In: Clinical and translational radiation oncology. 32 , p. 29-34 6 p.

Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial

Groen Veerle H, van Schie Marcel, Zuithoff Nicolaas P A, Monninkhof Evelyn M, Kunze-Busch Martina, de Boer Johannes C J, van der Voort van Zijp Jochem, Pos Floris J, Smeenk Robert Jan, Haustermans Karin, Isebaert Sofie, Draulans Cédric, Depuydt Tom, Verkooijen Helena M, van der Heide Uulke A, Kerkmeijer Linda G W 28 dec 2021, In: Radiotherapy & Oncology. 167 , p. 127-132 6 p.

Coronary artery calcifications on breast cancer radiotherapy planning CT scans and cardiovascular risk:What do patients want to know?

Gal Roxanne, Gregorowitsch Madelijn L., Emaus Marleen J., Blezer Erwin LA, van der Leij Femke, van Velzen Sanne GM, van Tol-Geerdink Julia J., Išgum Ivana, Verkooijen Helena M. dec 2021, In: International Journal of Cardiology: Cardiovascular Risk and Prevention. 11

Expectations of treatment outcomes in patients with spinal metastases; what do we tell our patients?:A qualitative study

Versteeg Anne L, Gal Roxanne, Charest-Morin Raphaele, Verlaan Jorrit-Jan, Wessels Hester, Fisher Charles G, Verkooijen Helena M 23 nov 2021, In: BMC Cancer. 21 , p. 1-8

Adaptive magnetic resonance-guided neurovascular-sparing radiotherapy for preservation of erectile function in prostate cancer patients

Teunissen Frederik R, Wortel Ruud C, Hes Jochem, Willigenburg Thomas, de Groot-van Breugel Eline N, de Boer Johannes C J, van Melick Harm H E, Verkooijen Helena M, van der Voort van Zyp Jochem R N okt 2021, In: Physics and Imaging in Radiation Oncology. 20 , p. 5-10 6 p.

Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic

Eijkelboom Anouk H, de Munck Linda, Lobbes Marc B I, van Gils Carla H, Wesseling Jelle, Westenend Pieter J, Guerrero Paez Cristina, Pijnappel Ruud M, Verkooijen Helena M, Broeders Mireille J M, Siesling Sabine, okt 2021, In: Preventive Medicine. 151 , p. 1-10 10 p.

The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients

Batenburg Marilot C. T., Maarse Wies, van der Leij Femke, Baas Inge O., Boonstra Onno, Lansdorp Nina, Doeksen Annemiek, van den Bongard HJGD, Verkooijen Helena M. sep 2021, In: Breast Cancer Research and Treatment. 189 , p. 425-433 9 p.

Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens

Jacobs Daphne H M, Charaghvandi Ramona, Horeweg Nanda, Maduro John H, Speijer Gabrielle, Roeloffzen Ellen M A, Mast Mirjam, Bantema-Joppe Enja, Petoukhova Anna L, van den Bongard Desirée H J G, Koper Peter, Crijns Anne P G, Marijnen Corrie A M, Verkooijen Helena M sep 2021, In: Breast Cancer Research and Treatment. 189 , p. 387-398 12 p.

Early health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling

Hehakaya Charisma, van der Voort van Zyp Jochem, Vanneste Ben, Grutters Janneke, Grobbee Diederick, Verkooijen Lenny, Frederix GW aug 2021, In: Radiotherapy & Oncology. 161 , p. 74-82 9 p.

Urethra and bladder dose-effect relations for genitourinary toxicity after EBRT for prostate cancer

Groen V., van Schie M., Zuithoff N. P., Monninkhof E. M., Kunze-Busch M., de Boer J. C., van Zijp J. van der Voort, Pos F. J., Smeenk R. J., Haustermans K., Isebaert S., Draulans C., Verkooijen H. M., van der Heide U. A., Kerkmeijer L. G. aug 2021, In: Radiotherapy and Oncology. 161 , p. S393-S395

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet